Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11868093 | 0.93 | KCNK3 (0.47) | ACHEPGRKCNK3KCNK9FLT1 | |
| SCHEMBL4618466 | 0.89 | PGR (0.46) | ACHEPGRKCNK3KCNK9FLT1 | |
| SCHEMBL12595 | 0.88 | — | — | |
| SCHEMBL6202698 | 0.88 | — | — | |
| SCHEMBL29567354 | 0.88 | — | — | |
| Sulfuric Acid SCHEMBL27923111 | 0.87 | KCNK3 (0.46) | ACHEPGRKCNK3KCNK9FLT1 | |
| Formaldehyde SCHEMBL28097742 | 0.86 | ACHE (0.52) | ACHEPGRKCNK3KCNK9SMN1; SMN2 | |
| Methane SCHEMBL29230318 | 0.85 | — | — | |
| Bromide SCHEMBL28516239 | 0.85 | ACHE (0.58) | ACHEPGRKCNK3KCNK9KMT2A | |
| M-Xylene SCHEMBL996903 | 0.85 | ACHE (0.67) | ACHELMNAPOLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103958475-B | Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-25 | — | — | CN | disclosed |
| CN-101878197-B | Method for producing 3-mercaptoaniline compound | IHARA CHEMICAL IND CO | 2015-01-07 | — | — | CN | disclosed |
| CN-103958475-A | Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases | HOFFMANN LA ROCHE | 2014-07-30 | — | — | CN | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101657449-B | Diphenyl-dihydro-imidazopyridinones | HOFFMANN LA ROCHE | 2012-06-06 | — | — | CN | disclosed |
| CN-101628888-B | Inhibitors of cytosolic phospholipase a2 | WYETH CORP | 2012-05-23 | — | — | CN | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| CN-101133026-B | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus | HOFFMANN LA ROCHE | 2011-07-06 | — | — | CN | disclosed |
| EP-2262791-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| EP-2260043-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal Gmbh (DE) | 2010-12-15 | — | — | EP | disclosed |
| CN-1972918-A | Pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | CN | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| CN-1751044-A | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2006-03-22 | — | — | CN | disclosed |
| CN-1617855-A | Cytosolic phospholipase A2Inhibitors | WYETH CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| US-20040266766-A1 | Selective urokinase inhibitors | WILEX AG (DE) | 2004-12-30 | — | — | US | disclosed |
| CN-1518445-A | Treatment of sexual dysfunction | 沃纳-兰伯特公司 | 2004-08-04 | — | — | CN | disclosed |
| CN-1479618-A | Treatment of sexual dysfunction with bombesin antagonists | ����-�����ع�˾ | 2004-03-03 | — | — | CN | disclosed |
| CN-1311783-A | Sulfonyl amino (thio) carbonyl triazoline (thi) one having alkenyl substitutents | BAYER AG (DE) | 2001-09-05 | — | — | CN | disclosed |
| CN-1196054-A | Herbicidal sulphonylamino (thio) carbonyl triazolin (thi) ones with heterocyclyl (alk) oxy substitutents | BAYER AG (DE) | 1998-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266766-A1 | Selective urokinase inhibitors | PLAU, PLAUR, SERPINE1 | ACHE 3446/4885PGR 2615/4885KCNK3 3694/4885 |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | ACHE 4713/4885PGR 3565/4885KCNK3 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.